Die Semaglutid-Medikamente wie Ozempic und Wegovy zielen auf den GLP-1-Signalweg, der an der Insulinausschttung, dem Appetit und der Magenentleerung beteiligt ist
Most claims center on alleged severe symptoms that go beyond expected tolerance issues, such as persistent vomiting, dehydration, inability to keep food down, or complications requiring ER care and other medical attention
And that drug is not on the market
You may think: Im not hungry, so I must be eating enough. Meanwhile your body is: Breaking down muscle tissue Suppressing hormone production Increasing injury risk Reducing recovery capacity Compromising immune function The IOCs updated RED-S consensus statement reinforced that low energy availability exists on a spectrum, not as an all-or-none condition (Mountjoy et al., 2023, British Journal of Sports Medicine)
Activating glucagon pathways may have metabolic advantages, but it also requires attention to glucose, heart rate, and overall tolerability